FINWIRES · TerminalLIVE
FINWIRES

Calix Launches New AI Cloud Features for Service Providers

By

Calix (CALX) said Wednesday it introduced new intelligence capabilities for its Agent Workforce Cloud platform that help service providers improve campaign measurement, simplify subscriber support, and strengthen network intelligence.

The company said the enhancements across its Engagement Cloud, Service Cloud and Operations Cloud products are designed to boost subscriber growth, speed issue resolution, improve reliability and lower operating costs.

Price: $41.41, Change: $+1.07, Percent Change: +2.64%

Related Articles

Wire

Ooma Fiscal Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Ooma (OOMA) reported fiscal Q1 adjusted earnings late Tuesday of $0.35 per diluted share, up from $0.20 a year earlier.Analysts polled by FactSet expected $0.32.Revenue in the three months ended April 30 rose to $81.1 million from $65 million a year earlier.Analysts surveyed by FactSet expected $79.8 million.Ooma expects fiscal Q2 adjusted EPS of $0.33 to $0.34 on revenue of $81.6 million to $82.3 million.Analysts polled by FactSet expect EPS of $0.31 on revenue of $80.2 million.The company boosted fiscal 2027 adjusted EPS guidance to $1.29 to $1.34 on revenue of $326 million to $328.5 million. Prior guidance was EPS of $1.26 to $1.31 on revenue of $321 million to $325 million.Analysts surveyed by FactSet expect EPS of $1.29 on revenue of $322.8 million.Ooma shares rose 4.8% in after-hours trading.

$OOMA
Wire

Jade Biosciences Says First Participant Dosed in First-in-Human Phase 1 Trial of JADE201

Jade Biosciences (JBIO) said late Tuesday the first participant has been dosed in a first-in-human phase 1 clinical trial of JADE201, an investigational, half-life extended, afucosylated monoclonal antibody.The first-in-human trial is a placebo-controlled study assessing single ascending doses of JADE201 in participants with rheumatoid arthritis, according to a statement.Jade said interim phase 1 data in rheumatoid arthritis anticipated in 2027 are expected to inform indication prioritization across potential autoimmune indications supported by B cell activating factor receptor biology.

$JBIO
Wire

Zscaler Fiscal Q3 Adjusted Earnings, Revenue Rise; Q4 Guidance Set

Zscaler (ZS) reported fiscal Q3 adjusted earnings late Tuesday of $1.08 per diluted share, up from $0.84 a year earlier.Analysts polled by FactSet expected $1.01.Revenue for the three months ended April 30 was $850.5 million, up from $678 million a year earlier.Analysts surveyed by FactSet expected $835.6 million.For fiscal Q4, the company expects adjusted EPS of $1.08 to $1.09 on revenue of $875 million to $878 million. Analysts expect EPS of $1.03 on revenue of $878.6 million.For the full-year fiscal 2026, the company now expects adjusted EPS of $4.10 to $4.11 on revenue of $3.329 billion to $3.332 billion. It earlier expected adjusted EPS of $3.99 to $4.02 on revenue of $3.31 billion to $3.32 billion.Analysts expect EPS of $4.01 on revenue of $3.32 billion.

$ZS